Everything You Need to Know About Moderna's Valuation

Everything You Need to Know About Moderna's Valuation

Shares of Moderna (NASDAQ: MRNA) have more than tripled so far this year as the biotech has quickly pushed its coronavirus vaccine, mRNA-1273, through the clinical trial process. Whether shares of Moderna can go even higher from here depends on multiple factors, some of which are out of the company's control. Will mRNA-1273 get through the clinical trial process and eventually gain regulatory approval?